Petrioli Roberto, Sabatino Marianna, Roviello Franco, Marrelli Daniele, Nastri Giacomo, Marsili Stefania, Correale Pierpaolo, Pozzessere Daniele, Messinese Simona, De Martino Antonio, Tani Francesco, Marzocca Giuseppe, Lorenzi Marco, Civitelli Serenella, Tanzini Gabriello, Pinto Enrico, Francini Guido
Department of Medical Oncology, University of Siena, Italy.
Hepatogastroenterology. 2005 Sep-Oct;52(65):1626-30.
BACKGROUND/AIMS: The aim of this study was to evaluate the survival benefit of adjuvant chemotherapy with etoposide, leucovorin and 5-fluorouracil (ELF) in gastric cancer patients undergoing previous surgery with a curative intent.
The clinical outcome of 49 patients with resected gastric cancer treated with adjuvant chemotherapy was compared with that of 85 surgically treated historical controls who did not receive any adjuvant treatment. The chemotherapy regimen consisted of six cycles of daily 1-hour intravenous infusions of folinic acid 100 mg/m2 and 5-FU 400 mg/ m2, and a 2-hour infusion of etoposide 100 mg/m2, for three days every 28 days.
The 5-year relapse-free survival was 32% in the adjuvant arm and 27% in the control arm (p = 0.6). At the last follow-up, there were 32 deaths in the adjuvant arm and 60 in the control arm. The median duration of survival was respectively 23 and 19 months, and the 5-year survival rates were 34% and 29% (p = 0.4). The chemotherapy was well tolerated.
Our data suggest that ELF adjuvant treatment is a safe and well tolerable combination chemotherapy in patients with resected gastric cancer, but it does not seem to improve prognosis in comparison with historical controls.
背景/目的：本研究旨在评估依托泊苷、亚叶酸钙和5-氟尿嘧啶（ELF）辅助化疗对接受过根治性手术的胃癌患者的生存获益情况。
将49例接受辅助化疗的胃癌切除患者的临床结局与85例未接受任何辅助治疗的手术治疗历史对照患者的结局进行比较。化疗方案为每28天进行3天，每天1小时静脉输注亚叶酸钙100mg/m²和5-氟尿嘧啶400mg/m²，以及2小时输注依托泊苷100mg/m²，共六个周期。
辅助化疗组的5年无复发生存率为32%，对照组为27%（p = 0.6）。在最后一次随访时，辅助化疗组有32例死亡，对照组有60例死亡。中位生存期分别为23个月和19个月，5年生存率分别为34%和29%（p = 0.4）。化疗耐受性良好。
我们的数据表明，ELF辅助治疗对胃癌切除患者是一种安全且耐受性良好的联合化疗，但与历史对照相比，似乎并未改善预后。
Zotero 插件